Antiviral activities of antibodies may either be dependent only on interactions between the
antibody and cognate antigen, as in binding and neutralization of an infectious virion, or …

Antibody dependent cellular cytotoxicity [ADCC] has been suggested to play an important
role in control of Human Immunodeficiency Virus-1 [HIV-1] viral load and protection from …

The RV144 HIV-1 trial of the canary pox vector (ALVAC-HIV) plus the gp120 AIDSVAX B/E
vaccine demonstrated an estimated efficacy of 31%, which correlated directly with antibodies …

The ALVAC-HIV/AIDSVAX-B/E RV144 vaccine trial showed an estimated efficacy of 31%.
RV144 secondary immune correlate analysis demonstrated that the combination of low …

Analysis of correlates of risk of infection in the RV144 HIV-1 vaccine efficacy trial demonstrated
that plasma IgG against the HIV-1 envelope (Env) variable region 1 and 2 inversely …

Among nonneutralizing HIV-1 envelope antibodies (Abs), those capable of mediating
antibody-dependent cellular cytotoxicity (ADCC) activity have been postulated to be important for …

We have developed a high‐throughput platform to detect the presence of HIV‐1 and SIV‐specific
ADCC‐mediating antibody responses. The assay is based on the hydrolysis of a cell‐…

INTRODUCTION Inducing protective antibodies is a key goal in HIV-1 vaccine development.
In acute HIV-1 infection, the dominant initial plasma antibody response is to the gp41 …

The RV144 ALVAC/AIDSVax HIV-1 vaccine clinical trial showed an estimated vaccine efficacy
of 31.2%. Viral genetic analysis identified a vaccine-induced site of immune pressure in …

HIV-1 mucosal transmission begins with virus or virus-infected cells moving through mucus
across mucosal epithelium to infect CD4 + T cells. Although broadly neutralizing antibodies (…